Peginterferon beta-1a

Peginterferon beta-1a
Clinical data
Trade names	Plegridy, Plegridy Pen
Other names	BIIB-017
AHFS/Drugs.com	Monograph
MedlinePlus	a614059
License data	US DailyMed: Peginterferon beta-1a;
Pregnancy; category	AU: D; ;
Routes of; administration	Subcutaneous injection
Drug class	Antineoplastic agent
ATC code	L03AB13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl);
CAS Number	1211327-92-2;
DrugBank	DB09122;
UNII	I8309403R0;
KEGG	D10483;
Chemical and physical data
Formula	C913H1417N246O256PS7 [C2H4O]n
Molar mass	44000 g·mol−1

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.